X T L Biopharmaceuticals reported $881.39M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.21M 2.2M Sep/2025
Bioline Rx USD 62.57M 24.47M Mar/2025
Teva Pharmaceutical Industries USD 1.15B 0 Dec/2025
X T L Biopharmaceuticals USD 881.39M 858.25M Jun/2025